Erlotinib-associated acute pneumonitis: Report of two cases

Canadian Respiratory Journal

Volumn 14, Issue 3, 2007, Pages 167-170

  Vahid, Bobbak ^a   Esmaili, Ali ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Drug induced lung injury; Epidermal growth factor receptor inhibitor; Erlotinib; Interstitial lung disease; Pneumonitis

Indexed keywords

CARBOPLATIN; CORTICOSTEROID; ERLOTINIB; METHYLPREDNISOLONE; PACLITAXEL; PREDNISONE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOCORTICOID; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CANCER RADIOTHERAPY; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG DOSE REDUCTION; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HOSPITAL DISCHARGE; HUMAN; HYPOXEMIA; INTERSTITIAL PNEUMONIA; INTUBATION; KLEBSIELLA; LUNG HEMORRHAGE; LUNG INFILTRATE; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; MALE; MEDICAL LITERATURE; METASTASIS; PRIORITY JOURNAL; REHABILITATION CENTER; RESPIRATORY FAILURE; SEPSIS; ACUTE DISEASE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; FATALITY; LUNG TUMOR; MIDDLE AGED; PNEUMONIA; SEPTIC SHOCK;

ACUTE DISEASE; ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FATAL OUTCOME; FEMALE; GLUCOCORTICOIDS; HUMANS; LUNG NEOPLASMS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PNEUMONIA; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SHOCK, SEPTIC;

EID: 34249951416     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/832605     Document Type: Article

References (16)

1. Higenbottam T, Kuwano K, Nemery B, Fujita Y. Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 2004;91(Suppl 2):S31-7.
2. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91(Suppl 2):S18-23.
3. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist 2005;10:461-6.
4. Mancuso A, Sternberg CN. New treatments for metastatic kidney cancer. Can J Urol 2005;12(Suppl 1):66-70.
5. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent of metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85.
6. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97:880-7.
7. Gordon AN, Finkler N, Edwards RP, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study. Int J Gynecol Cancer 2005;15:785-92.
8. Dargovich T, Patnaik A, Rowinsky EK, et al. A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies. Proc Am Soc Clin Oncol 2003;22:223. (Abst)
9. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-63.
10. Yamamoto N, Yamada Y, Shimoyama T, et al. A phase I study of erlotinib HCl in Japanese patients with various types of solid tumors. Proc Am Soc Clin Oncol 2003;22:225. (Abst)
11. Tan AR, Yang X, Berman A, et al. Evaluation of epidermal growth factor receptor signaling in tumor and skin biopsies after treatment with OSI-774 in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2003;22:196. (Abst)
12. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
14. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
15. Tammaro KA, Baldwin PD, Lundberg AS. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). J Oncol Pharm Pract 2005;11:127-30.
16. Muller NL, White DA, Jiang H, Gemma A. Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 2004;91(Suppl 2):S24-30.